Hassounah et al., 2017 - Google Patents
Inhibition of ciliogenesis promotes hedgehog signaling, tumorigenesis, and metastasis in breast cancerHassounah et al., 2017
View HTML- Document ID
- 15880083177711745002
- Author
- Hassounah N
- Nunez M
- Fordyce C
- Roe D
- Nagle R
- Bunch T
- McDermott K
- Publication year
- Publication venue
- Molecular Cancer Research
External Links
Snippet
Primary cilia are chemosensors that play a dual role to either activate or repress Hedgehog signaling, depending on presence or absence of ligand, respectively. While inhibition of ciliogenesis has been shown to be characteristic of breast cancers, the functional …
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hassounah et al. | Inhibition of ciliogenesis promotes hedgehog signaling, tumorigenesis, and metastasis in breast cancer | |
| Nacarelli et al. | NAMPT inhibition suppresses cancer stem-like cells associated with therapy-induced senescence in ovarian cancer | |
| Dong et al. | Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation | |
| Liu et al. | UBE2C is upregulated by estrogen and promotes epithelial–mesenchymal transition via p53 in endometrial cancer | |
| Moon et al. | The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling | |
| Wang et al. | Senescent carcinoma-associated fibroblasts upregulate IL8 to enhance prometastatic phenotypes | |
| Li et al. | Gas1 inhibits metastatic and metabolic phenotypes in colorectal carcinoma | |
| Schrecengost et al. | USP22 regulates oncogenic signaling pathways to drive lethal cancer progression | |
| Hagan et al. | Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis | |
| Mortezavi et al. | KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy | |
| McCarroll et al. | βIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non–small cell lung cancer | |
| Shi et al. | TFAP2A regulates nasopharyngeal carcinoma growth and survival by targeting HIF-1α signaling pathway | |
| Li et al. | Overexpression of CXCR4 is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in epithelial ovarian cancer | |
| Hunt et al. | Cytoplasmic cyclin E predicts recurrence in patients with breast cancer | |
| Verma et al. | Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells | |
| Lin et al. | Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer | |
| Evans et al. | XIAP regulation by MNK links MAPK and NFκB signaling to determine an aggressive breast cancer phenotype | |
| Hirata et al. | MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer | |
| Ma et al. | SALL1 functions as a tumor suppressor in breast cancer by regulating cancer cell senescence and metastasis through the NuRD complex | |
| Liu et al. | Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer | |
| Salem et al. | Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition | |
| Wu et al. | Therapeutic targeting of BRD4 in head neck squamous cell carcinoma | |
| Zou et al. | FBXO31 suppresses gastric cancer EMT by targeting Snail1 for proteasomal degradation | |
| Koutsami et al. | Centrosome abnormalities are frequently observed in non‐small‐cell lung cancer and are associated with aneuploidy and cyclin E overexpression | |
| Kosaka et al. | Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion |